Treating ‘genetic privacy’ like it’s just one thing keeps us from understanding people’s concerns
By Angela Chen,
The Verge
| 10. 31. 2018
“Genetic privacy” is a complicated concept, and a new study finds that decoding how people feel about the idea is equally complex.
Genetic data can be collected for medical purposes, like genetic testing for hereditary diseases, by the government for identification purposes, or submitted to private companies that promise to tell you more about yourself and your ancestry. But increasingly, researchers are realizing that people’s expectations for how their data might be used aren’t lining up with reality.
For a study published today in the journal PLOS One researchers analyzed 53 studies (covering over 47,000 participants) that looked at how the general public, professionals, and patients viewed genetic privacy. The results paint a complex picture, says study author Ellen Clayton, a professor of law and health policy at Vanderbilt University. If you ask people “are you worried about genetic privacy?” most will say yes. But if you ask a patient whose genetic data was collected for medical testing about a more specific situation, like “are you concerned about sharing data with third parties?” the answers can vary widely.
For...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...